Anti Influenza Virus Medicine Market

Chinese medicine has thousands of years of history in suppressing viruses, and has accumulated rich experience in the prevention and treatment of influenza.

Anti Influenza Virus Medicine Market contains market size and forecasts of Anti Influenza Virus Chinese Medicine in global, including the following market information:

Global Anti Influenza Virus Chinese Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Anti Influenza Virus Chinese Medicine Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Anti Influenza Virus Chinese Medicine companies in 2021 (%)

The global Anti Influenza Virus Chinese Medicine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Solution Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti Influenza Virus Chinese Medicine include Guangzhou Pharmaceutical, CR SANJIU, TASLY, China TCM, Yunnan Baiyao, Tongrentang, Jumpcan, Zhejiang Conba Pharmaceutical and Green Valley Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Anti Influenza Virus Chinese Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti Influenza Virus Chinese Medicine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti Influenza Virus Chinese Medicine Market Segment Percentages, by Type, 2021 (%)

Oral Solution

Capsule

Lozenges

Chewable Tablets

Aerosol

Injection

Pills

Particles

Syrup

Global Anti Influenza Virus Chinese Medicine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti Influenza Virus Chinese Medicine Market Segment Percentages, by Application, 2021 (%)

Adult

Children

Global Anti Influenza Virus Chinese Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Anti Influenza Virus Chinese Medicine Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Anti Influenza Virus Chinese Medicine revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Anti Influenza Virus Chinese Medicine revenues share in global market, 2021 (%)

Key companies Anti Influenza Virus Chinese Medicine sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Anti Influenza Virus Chinese Medicine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Guangzhou Pharmaceutical

CR SANJIU

TASLY

China TCM

Yunnan Baiyao

Tongrentang

Jumpcan

Zhejiang Conba Pharmaceutical

Green Valley Pharma

Changbaishan Pharmaceutical

Zhejiang Kanglaite Pharmaceutical

Qingfeng Pharmaceutical Group

Buchang Pharmaceutical

Livzon

ZBD Pharmaceutical

Chase Sun Pharmaceutical

Wuzhou Pharmaceutical

Yusheng Pharmaceutical

Harbin Pharmaceutical Group

Fusen Pharmaceutical

Gerun Pharmaceutical

Shineway Pharmaceutical

Yiling Pharmaceutical

Harbin Pharmaceutical Group